Special use-results survey of ENAROY Tablets (long-term use)

JRCT ID: jRCT2031210549

Registered date:07/01/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Anemia associated with CKD
• Date of first enrollment: 04/03/2022
• Target sample size: 1500
• Study type: Observational

Outcome(s)

Primary Outcome

-Incidence of onset of thromboembolism
-Incidence of onset of hypertension
-Incidence of cardiovascular events (excluding thromboembolism)
-Incidence of onset of retinal hemorrhage
-Incidence of onset of malignant tumor
-Incidence of progressed disease in patients with autosomal dominant polycystic kidney disease (ADPKD)

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

(1) Patients using Enaroy for the first time for nephrogenic anemia
(2) Patients must provide informed consent before the start

• Exclude criteria: none

Related Information

• Primary Sponsor: Patient Safety and Pharmacovigilance Dept.